Market accessOfficial
MSD to end Emend (aprepitant) marketing in EU/EEA; Italy's 125 mg + 80 mg capsules go from 30 November
🇮🇹 AIFA · Mon 16 Nov 2026
AIFA says the withdrawal is commercial and unrelated to safety, efficacy or quality, and asks healthcare professionals to review ongoing treatment plans.
The Italian Medicines Agency (AIFA) published a notice on 16 November 2026 on the definitive cessation of marketing of Emend (aprepitant). MSD Italia S.r.l., the local representative of Merck Sharp & Dohme B.V., told AIFA and other European regulators that the product will permanently leave the market in the European Union and European Economic Area.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
More Market access
All →
China adds Ascentage's lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation
Ascentage Pharma Group International (AAPG) · Mon 16 Nov 2026
INFARMED updates Portugal's reference price groups for fourth quarter of 2026
🇵🇹 INFARMED · Mon 16 Nov 2026
AIFA updates Italy's Transparency Lists of generics and reference prices as of 16 November
🇮🇹 AIFA · Mon 16 Nov 2026
ANSM issues new accreditation rules for external quality control bodies, repealing 2019 order
🇫🇷 ANSM · Mon 16 Nov 2026
AIFA publishes updated transparency lists with generic reference prices as of 16 November
🇮🇹 AIFA · Mon 16 Nov 2026
Estonia's human medicines market grows 11.7% in third quarter of 2026
🇪🇪 Ravimiamet · Mon 16 Nov 2026